Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

MLA

Al-Batran, Salah-Eddin, et al. “Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.” The Oncologist, vol. 25, no. 8, Aug. 2020, pp. e1181–87. EBSCOhost, https://doi.org/10.1634/theoncologist.2020-0109.

APA

Al-Batran, S.-E., Moorahrend, E., Maintz, C., Goetze, T. O., Hempel, D., Thuss-Patience, P., Gaillard, V. E., & Hegewisch-Becker, S. (2020). Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. The Oncologist, 25(8), e1181–e1187. https://doi.org/10.1634/theoncologist.2020-0109

Chicago

Al-Batran, Salah-Eddin, Enno Moorahrend, Christoph Maintz, Thorsten O Goetze, Dirk Hempel, Peter Thuss-Patience, Vincent E Gaillard, and Susanna Hegewisch-Becker. 2020. “Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.” The Oncologist 25 (8): e1181–87. doi:10.1634/theoncologist.2020-0109.